Drugs / GPA33-CC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07590856 | May 2026 → Dec 2027 expected | colorectal cancer | SmartNuclide Biopharma | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPA33-CC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07590856 ↗ |
| Modality | Protein / enzyme biologic | “GPA33-CC protein dosage 0.3mg/kg” NCT07590856 ↗ |
| Route | Intravenous | “SNA028 is a two-step radioimmunotherapy, delivered as two separate products GPA33-CC and 177Lu-SmartD2, both will be administered as an IV infusion.” NCT07590856 ↗ |